| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.23.1.79 |
| P953 | full work available at URL | https://europepmc.org/articles/pmc184621?pdf=render |
| https://europepmc.org/articles/PMC184621 | ||
| https://europepmc.org/articles/PMC184621?pdf=render | ||
| https://journals.asm.org/doi/pdf/10.1128/AAC.23.1.79 | ||
| P932 | PMC publication ID | 184621 |
| P698 | PubMed publication ID | 6338821 |
| P5875 | ResearchGate publication ID | 16857110 |
| P2093 | author name string | A. Polak | |
| A. R. Waldorf | |||
| P2860 | cites work | Mode of action of 5-fluorocytosine | Q28324390 |
| Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size | Q34981907 | ||
| 5-fluorocytosine resistance in Cryptococcus neoformans | Q35650214 | ||
| Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States | Q35716914 | ||
| The Influence of 5-FIuorocytosine on Nucleic Acid Synthesis in <i>Candida albicans, Cryptococcus neoformans</i>, and <i>Aspergillus fumigatus</i> | Q40772082 | ||
| 5-Fluorocytosine--current status with special references to mode of action and drug resistance | Q40857255 | ||
| The Effect of 5-Fluorocytosine on the Blastospores and Hyphae of Candida Albicans | Q41022343 | ||
| Macromolecular syntheses during the cell cycles of yeast and hyphal phases of Candida albicans | Q46834916 | ||
| Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. | Q52163855 | ||
| Fungistatic Activity, Uptake and Incorporation of 5-Fluorocytosine in <i>Candida albicans, </i>as Influenced by Pyrimidines and Purines. I. Reversal Experiments | Q53809080 | ||
| Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance | Q54631149 | ||
| Fungistatic activity, uptake and incorporation of 5-fluorocytosine in Candida albicans, as influenced by pyrimidines and purines. II. Studies on distribution and incorporation | Q69303462 | ||
| The effect of 5-fluorocytosine on the synthesis of 80S ribosomes by pathogenic fungi | Q70958619 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| 5-fluorocytosine | Q238490 | ||
| P304 | page(s) | 79-85 | |
| P577 | publication date | 1983-01-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Mechanisms of action of 5-fluorocytosine | |
| P478 | volume | 23 |
| Q39921656 | 19F nuclear magnetic resonance analysis of 5-fluorouracil metabolism in wild-type and 5-fluorouracil-resistant Nectria haematococca |
| Q39816994 | 19F nuclear magnetic resonance study of fluoropyrimidine metabolism in strains of Candida glabrata with specific defects in pyrimidine metabolism |
| Q33341541 | 5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study |
| Q39834442 | A 19F nuclear magnetic resonance study of uptake and metabolism of 5-fluorocytosine in susceptible and resistant strains of Candida albicans |
| Q37409933 | A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis |
| Q90005107 | A novel screening system based on gene targeting to enrich the modified mammalian cells: without leaving selection marker and additional sequence |
| Q36235037 | An update on antifungal targets and mechanisms of resistance in Candida albicans |
| Q39867085 | Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum |
| Q39685115 | Anti-Candida drugs--the biochemical basis for their activity |
| Q36332565 | Anticandidal low molecular compounds from higher plants with special reference to compounds from essential oils |
| Q35575367 | Antifungal properties of peptidomimetics with an arginine-[β-(2,5,7-tri-tert-butylindol-3-yl)alanine]-arginine motif against Saccharomyces cerevisiae and Zygosaccharomyces bailii. |
| Q34335225 | Antifungal resistance among Candida species |
| Q39751373 | Antifungal resistance and new strategies to control fungal infections |
| Q33775256 | Candida infections and their prevention |
| Q36944929 | Clonal population of flucytosine-resistant Candida tropicalis from blood cultures, Paris, France |
| Q46641699 | Cytosine deaminase MX cassettes as positive/negative selectable markers in Saccharomyces cerevisiae |
| Q35336154 | Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections |
| Q54394043 | Drug resistance in Candida albicans and Candida glabrata. |
| Q38713544 | EC-tagging allows cell type-specific RNA analysis |
| Q38016754 | Emerging implications of nonmammalian cytosine deaminases on cancer therapeutics |
| Q54023662 | In vitro susceptibility of Candida albicans isolates from apical and marginal periodontitis to common antifungal agents. |
| Q35076919 | Inhibition of nucleic acid biosynthesis makes little difference to formation of amphotericin B-tolerant persisters in Candida albicans biofilm |
| Q33227090 | Limenin, a defensin-like peptide with multiple exploitable activities from shelf beans |
| Q35005086 | Loss of heterozygosity of FCY2 leading to the development of flucytosine resistance in Candida tropicalis |
| Q40497992 | Mode of Action of a Designed Antimicrobial Peptide: High Potency against Cryptococcus neoformans |
| Q40289630 | Molecular mechanisms of primary resistance to flucytosine in Candida albicans |
| Q84551050 | Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata |
| Q39834979 | Noninvasive and quantitative 19F nuclear magnetic resonance study of flucytosine metabolism in Candida strains |
| Q35647796 | Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. |
| Q38837629 | Persistence and drug tolerance in pathogenic yeast. |
| Q38193337 | Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. |
| Q57533011 | Pharmacology of Systemic Antifungal Agents |
| Q53166301 | Phosphorylation of thymidylate synthase affects slow-binding inhibition by 5-fluoro-dUMP and N(4)-hydroxy-dCMP. |
| Q60175850 | Pre-Existing Liver Disease and Toxicity of Antifungals |
| Q93227330 | Probing the evolutionary robustness of two repurposed drugs targeting iron uptake in Pseudomonas aeruginosa |
| Q40844582 | Profiling of the effects of antifungal agents on yeast cells based on morphometric analysis |
| Q36602123 | Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types |
| Q92071802 | Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris |
| Q34643153 | Saccharomyces cerevisiae biofilm tolerance towards systemic antifungals depends on growth phase |
| Q30984298 | Simultaneous determination of flucytosine and fluorouracil in human plasma by high-performance liquid chromatography |
| Q39820297 | Study of the metabolism of flucytosine in Aspergillus species by 19F nuclear magnetic resonance spectroscopy |
| Q37765817 | Synthesis and biological evaluation of amphotericin B derivatives |
| Q34854161 | The synthetic amphipathic peptidomimetic LTX109 is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent manner |
| Q35598950 | Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method |
| Q28481716 | Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis |
Search more.